Speaker Profile
M.D., FRSPH, Global Development Lead for Clinical Development Oncology & Hematology, Pfizer
Biography
Shreya Badhrinarayanan, MD leads advancements in ADCs and IO biologics within hematology and oncology at Pfizer.Previously at Genentech, she provided strategic direction for the development of new Immuno-Oncology drugs by leading cross-functional teams. Earlier in her career, she served as a Physician with the National Health Service, where she made significant contributions to clinical and research initiatives.Thriving in the field of medical leadership and management, Dr. Badhrinarayanan received the Edward Jenner Award from the NHS Leadership Academy. To further her passion for teaching, she served as an Honorary Lecturer in Medical Education and Simulation at the University of Adelaide Medical School, Australia. Her wide range of interests varies from AI in health care to DI initiatives that have been embodied through her contributions to print and media as well as at conferences across the globe. In addition, she is the editorreviewer of numerous high-impact journals, including the British Medical Journal.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
• Shannon Turley, Amgen
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
Fireside Chat: Immune Tolerance to Cure
• Mary E. Brunkow, ISB - 2025 Nobel Laureate
• Lee Hood, Phenome Health
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• S. Peter Kang, Daiichi Sankyo
• Vadim Koshkin, UC San Francisco
Radiopharmaceutical Therapy: New Targets, Isotopes, and Challenges
• Chair: William Oh, Yale
• Munir Ghesanim, United Theranostics
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Anne Kasmar, Parexel
• Jedd D. Wolchok, Weill Cornell Medicine
• Roy S. Herbst, Yale
Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Combinations
• Chair: Levi Garraway, Roche
